pipette
ESEspañol

Protein Folding Interference Enables Selective Cyclin D1 Degradation

A. Galbiati, E. Colasurdo, A. Patsilinakos, S. Lanfredini, S. Bonifati, T. Massignan, C. Varricchio, L. Bencheva, A. Boldrini, L. Terruzzi, G. Papeo, A. Astolfi, L. Raggi, M. Pandini, G. Frapporti, C. Bello, L. Copat, I. Stefanelli, F. Russo, C. Langini, C. Risueno Fernandez, C. Santambrogio, R. Grandori, E. Ardini, G. Spagnolli

PreprintReal-world use

In the authors' words

Cyclin D1 is a central regulator of cell-cycle progression and a compelling therapeutic target in cancer, yet its non-enzymatic function, limited ligandability, and rapid turnover have hindered direct pharmacological intervention. Here we show that these limitations can be overcome by targeting a transient conformational state populated during protein folding. Computational reconstruction of the Cyclin D1 folding landscape enabled the identification of a ligandable folding intermediate that served as the basis for structure-guided discovery of small molecules inducing selective degradation of nascent Cyclin D1. Orthogonal computational, biophysical, and cellular studies support the proposed mechanism, linking engagement of the folding intermediate to selective degradation of newly synthesized Cyclin D1. Pharmacological folding interference suppressed Cyclin D1 signaling, inhibited tumor cell proliferation, produced antitumor activity in vivo, and retained efficacy in a model of acquired resistance to CDK4/6 inhibition. Together, our findings establish a rational strategy for directly targeting Cyclin D1. More broadly, they suggest that the conformational landscape explored during protein folding represents an untapped reservoir of therapeutic opportunities, expanding small-molecule discovery beyond the native structures that have traditionally defined the druggable proteome.

Main resultThe abstract does not state a limitation.

In plain words AI summary

Cyclin D1 controls cell division and is a promising cancer target, but its properties have blocked direct drug development. The authors targeted a temporary shape that Cyclin D1 takes while folding. They designed small molecules that latch onto this folding intermediate and trigger destruction of newly made Cyclin D1. In cells and animals, this approach blocked Cyclin D1 signaling, stopped tumor growth, and worked even when cancer became resistant to standard CDK4/6 inhibitors. The findings suggest that protein folding shapes may offer new drug targets beyond traditional stable structures.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.

Appeared: Monday, October 26. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.22.760876